Charmacy Pharmaceutical Co., Ltd. (HKG:2289)
Hong Kong · Delayed Price · Currency is HKD 5.50
0.00 (0.00%)
At close: Oct 21, 2026
Charmacy Pharmaceutical Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 4,610 | 4,329 | 4,385 | 4,348 | 4,141 | 3,763 |
Other Revenue | 68.07 | 55.3 | 50.34 | 56.11 | 34.61 | 30.55 |
| 4,678 | 4,385 | 4,435 | 4,404 | 4,175 | 3,794 | |
Revenue Growth | 10.23% | -1.15% | 0.72% | 5.47% | 10.06% | -4.96% |
Cost of Revenue | 4,343 | 4,049 | 4,115 | 4,115 | 3,907 | 3,560 |
Gross Profit | 334.52 | 336.01 | 320.88 | 288.38 | 268.61 | 234.12 |
Selling, General & Admin | 181.63 | 181.37 | 175.27 | 170 | 162.57 | 151.85 |
Other Operating Expenses | 9.21 | 9.55 | 10.23 | 9.3 | 10.07 | 8.13 |
Operating Expenses | 208.78 | 204.47 | 185.56 | 180.11 | 175.12 | 159.69 |
Operating Income | 125.74 | 131.54 | 135.31 | 108.28 | 93.49 | 74.42 |
Interest Expense | -54.71 | -56.83 | -60.65 | -41.93 | -35.07 | -41.52 |
Interest & Investment Income | 3.59 | 2.2 | 3.98 | 4.3 | 4.6 | 3.8 |
Currency Exchange Gain (Loss) | 0.18 | 0.09 | -0.26 | -0.36 | -0.75 | 0.14 |
Other Non Operating Income (Expenses) | -4.71 | -8.79 | -7.13 | -4.11 | -6.99 | -4.01 |
EBT Excluding Unusual Items | 70.1 | 68.21 | 71.25 | 66.17 | 55.28 | 32.83 |
Impairment of Goodwill | - | - | -0.03 | - | - | - |
Gain (Loss) on Sale of Investments | - | - | - | -0.1 | - | - |
Gain (Loss) on Sale of Assets | -0.16 | -0.18 | 0.31 | 0.05 | 65.84 | 0.15 |
Asset Writedown | 0.01 | 0.01 | -0.33 | -0.01 | - | -0.01 |
Other Unusual Items | -3.71 | -3.74 | -0.01 | 1.32 | 0.94 | 0.01 |
Pretax Income | 66.24 | 64.31 | 71.19 | 67.42 | 122.05 | 32.98 |
Income Tax Expense | 19.15 | 18.04 | 17.91 | 16.07 | 31.58 | 9.83 |
Earnings From Continuing Operations | 47.09 | 46.27 | 53.28 | 51.34 | 90.47 | 23.15 |
Net Income | 47.09 | 46.27 | 53.28 | 51.34 | 90.47 | 23.15 |
Net Income to Common | 47.09 | 46.27 | 53.28 | 51.34 | 90.47 | 23.15 |
Net Income Growth | -2.46% | -13.16% | 3.78% | -43.25% | 290.76% | -42.91% |
Shares Outstanding (Basic) | 108 | 108 | 108 | 108 | 108 | 108 |
Shares Outstanding (Diluted) | 108 | 108 | 108 | 108 | 108 | 108 |
Shares Change | 0.01% | -0.01% | -0.01% | 0.00% | 0.01% | -0.01% |
EPS (Basic) | 0.44 | 0.43 | 0.49 | 0.48 | 0.84 | 0.21 |
EPS (Diluted) | 0.44 | 0.43 | 0.49 | 0.48 | 0.84 | 0.21 |
EPS Growth | -2.46% | -13.15% | 3.79% | -43.25% | 290.72% | -42.90% |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | 315.44 | 263.42 | 90.31 | -137.39 | 35.46 | -44.58 |
Free Cash Flow Per Share | 2.92 | 2.44 | 0.84 | -1.27 | 0.33 | -0.41 |
Dividend Per Share | 0.300 | 0.300 | 0.450 | 0.300 | 0.450 | - |
Dividend Growth | -33.33% | -33.33% | 50.00% | -33.33% | 125.00% | - |
Gross Margin | 7.15% | 7.66% | 7.23% | 6.55% | 6.43% | 6.17% |
Operating Margin | 2.69% | 3.00% | 3.05% | 2.46% | 2.24% | 1.96% |
Profit Margin | 1.01% | 1.05% | 1.20% | 1.17% | 2.17% | 0.61% |
Free Cash Flow Margin | 6.74% | 6.01% | 2.04% | -3.12% | 0.85% | -1.18% |
EBITDA | 145.57 | 152.14 | 167.48 | 129.95 | 121.03 | 103.52 |
EBITDA Margin | 3.11% | 3.47% | 3.78% | 2.95% | 2.90% | 2.73% |
D&A For EBITDA | 19.84 | 20.6 | 32.17 | 21.68 | 27.54 | 29.09 |
EBIT | 125.74 | 131.54 | 135.31 | 108.28 | 93.49 | 74.42 |
EBIT Margin | 2.69% | 3.00% | 3.05% | 2.46% | 2.24% | 1.96% |
Effective Tax Rate | 28.91% | 28.05% | 25.16% | 23.84% | 25.87% | 29.80% |
Revenue as Reported | 4,678 | 4,385 | 4,435 | 4,404 | 4,175 | 3,794 |
Advertising Expenses | - | 1.85 | 6.08 | 11.52 | 8.89 | 9.22 |